Last updated on December 2016

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer


Brief description of study

To demonstrate non-inferiority of CJ-12420 to lansoprazole 30 mg capsule in terms of therapeutic efficacy, and to confirm safety of CJ-12420, after once daily oral administration of CJ-12420 50 mg, 100 mg or Lansoprazole 30 mg capsule in gastric ulcer patients.

Detailed Study Description

This is a double blind, randomized, placebo-controlled, phase 3 study. Subjects will be randomly assigned to one of the three treatment groups (CJ-12420 50 mg, 100 mg or Lansoprazole 30 mg).

Clinical Study Identifier: NCT02761512

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Ahrong Kim

Catholic Univ. Seoul St. Mary Hospita
Seoul, Korea, Republic of
  Connect »

Ahrong Kim

Kyung Hee University Medical Center
Seoul, Korea, Republic of
  Connect »